TIBER CREEK GROUP

Lobbying for ALNYLAM PHARMACEUTICALS, INC. · Biopharmaceuticals.

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2025 · Massachusetts · House · Senate · $60,000.00 income · posted Jul 19, 2025

Bills named in this filing 3

Lobbying activity 1

Medicare/Medicaid

Issues related to H.R. 946/S.1862 - ORPHAN Cures Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.